1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Vimian Group AB (publ)

Vimian Group AB (publ)

VIMGF
Vimian Group AB (publ)US flagOther OTC
2.77
USD
- -
- -
1.46BMarket Cap
Vimian Group AB (publ)
VIMGF
(Other OTC)

Recent

price

2.77

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.02
0.06
2.78
0.48
0.68
0.71
0.74
0.81
0.77
Revenue per Share
- -
- -
- -
2.06
0.02
-0.02
0.02
0.04
0.06
0.04
Basic EPS, GAAP
- -
-0.01
- -
-0.03
0.01
0.04
-0.09
0.09
0.17
0.13
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.01
1.98
0.17
0.13
0.13
0.16
0.21
0.17
Book Value per Share
- -
0.01
-0.01
-2.8
-0.33
-0.45
-0.41
-0.19
-0.23
-0.26
Tangible Book Value per Share
- -
402
402
26
361
416
468
504
526
524
Basic Weighted Avg Shares
- -
8
25
71
173
281
332
375
425
404
Sales/Revenue/Turnover
- -
-2.74
4.71
14.6
14.84
16.08
13.08
13.21
15.91
13.06
Operating Margin (%)
- -
1
3
7
17
27
32
34
38
35
Depreciation Expense
- -
-1
-1
53
7
-7
10
18
31
23
Net Income, GAAP
- -
- -
- -
5.81
39.19
879
46.39
32.87
29.41
34.7
Effective Tax Rate (%)
- -
-9.75
-5.12
74.12
3.8
-2.4
2.95
4.94
7.36
5.61
Profit Margin (%)
- -
1
-1
14
59
40
84
113
104
136
Working Capital
- -
6
13
76
170
216
310
229
234
289
LT Debt
- -
20
52
274
359
481
527
706
709
692
Total Equity
- -
- -
- -
4.47
3.42
-56.05
2.98
3.7
5.01
3.7
Return on Invested Capital (%)
- -
- -
- -
52.72
4.43
-35.84
5.99
9.94
13.19
6.64
Return on Capital (%)
- -
- -
- -
- -
11.9
-11.9
16.83
25.55
32.83
28.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
5
5
5
LT Borrowings
216
207
278
LT Finance Leases
13
12
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
524
524
527
Market Capitalization
1,702
1,746
1,772

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
223
224
230
Cash, Cash Equivalents & STI
65
60
68
Accounts Receivable, Net
55
63
59
Inventories
78
78
80
Total Current Liabilities
110
120
94
Payables & Accruals
- -
- -
- -
ST Debt
5
5
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
21.78%
0.33%
Free Cash Flow
- -
-184.57%
106.38%
Net Income, GAAP
- -
-75.46%
69.19%
Sales/Revenue/Turnover
- -
49.99%
13.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
91
91
88
105
375
2025
108
104
109
- -
425
2026
116
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
- -
0.02
0.04
2025
0.01
0.02
0.02
- -
0.06
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
WuXi AppTec Co., Ltd. (WUXAY)
Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
Thalys Medical Technology Group Inc. (603716.SS)
Applied DNA Sciences, Inc. (APDN)
Predilife S.A. (ALPRE.PA)
Shin Nippon Biomedical Laboratories, Ltd. (2395.T)
Business
Vimian Group AB (publ) is a global animal health company focused on specialty pharmaceuticals, medical technology, veterinary services and diagnostics for companion animals. Headquartered in Stockholm, Sweden, and founded in 2015, the company operates through key brands including Nextmune in specialty pharma; Movora in medtech; VetFamily in veterinary services; and Indical Bioscience in diagnostics, offering proprietary diagnostics, prescription and non-prescription treatments for preventive care and chronic conditions such as allergy, dermatology, specialised nutrition and specialty pharmaceuticals; orthopedic implants, power tools, instruments, sutures and adjunct products comprising approximately 6,000 items; veterinary clinic management platforms and services; and laboratory diagnostics reaching over 17,000 veterinary clinics and 1,700 labs across more than 80 markets with around 1,200 employees and annual revenues of approximately EUR 375 million. Vimian targets veterinarians, laboratories and pet owners worldwide, delivering innovative solutions through forward-leaning R&D, global distribution and professional training. In recent developments, Vimian acquired AllAccem Inc. in June 2025 to expand its veterinary dental sealant offerings; IMEX Veterinary Inc. in August 2025 to strengthen orthopedic implants and external fixation; iM3 Dental Limited and iM3 Pty Ltd in September 2024 for veterinary dental products and equipment; and product portfolios of veterinary surgical instruments and orthopedic implants, alongside appointing Alireza Tajbakhsh as CEO effective November 2025 and adopting new financial targets emphasizing double-digit organic growth, margin expansion and value-creative acquisitions following 32 deals that doubled revenues.

Company News

APIChatGPT

  • seekingalpha.com

    Vimian Group AB (publ) (VIMGF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Vimian Group AB (publ) (VIMGF) Q1 2026 Earnings Call Transcript

  • seekingalpha.com

    Vimian Group AB (publ) (VIMGF) Q4 2025 Earnings Call Transcript